The effectiveness and value of fezolinetant for moderate-to-severe vasomotor symptoms associated with menopause: A summary from the Institute for Clinical and Economic Review's Midwest Public Advisory Council

被引：0
作者：
Wright, Abigail C. [1 ]
Beaudoin, Francesca L. [1 ]
McQueen, R. Brett [2 ]
Yeung, Kai [3 ]
Moradi, Ashton [1 ]
Herron-Smith, Serina [1 ]
Gutierrez, Eric [2 ]
Lin, Grace A. [1 ]
Pearson, Steven [1 ]
机构：
[1] Inst Clin & Econ Review, Boston, MA 02108 USA
[2] Brown Univ, Dept Epidemiol, Providence, RI USA
[3] Kaiser Permanente Washington Hlth Res Inst, Seattle, WA USA
来源：
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY | 2023年 / 29卷 / 06期
关键词：
QUALITY-OF-LIFE; LOW-DOSE ESTRADIOL; POSTMENOPAUSAL WOMEN; HOT FLASHES; HORMONE-THERAPY; DOUBLE-BLIND; MG; EFFICACY; PLACEBO; DESVENLAFAXINE;
D O I：
暂无
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
引用
收藏
页码：692 / 698
页数：7
相关论文
共 45 条
  • [1] [Anonymous], 2022, ASTELLAS SUBMITS FEZ
  • [2] A randomized, double- blind, placebo- controlled study of the lowest effective dose of drospirenone with 17β- estradiol for moderate to severe vasomotor symptoms in postmenopausal women
    Archer, David F.
    Schmelter, Thomas
    Schaefers, Matthias
    Gerlinger, Christoph
    Gude, Kerstin
    [J]. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2014, 21 (03): : 227 - 235
  • [3] Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety
    Archer, David F.
    Dupont, Caroline M.
    Constantine, Ginger D.
    Pickar, James H.
    Olivier, Sophie
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2009, 200 (03) : 238.e1 - 238.e10
  • [4] A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause
    Archer, David F.
    Seidman, Larry
    Constantine, Ginger D.
    Pickar, James H.
    Olivier, Sophie
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2009, 200 (02) : 172.e1 - 172.e10
  • [5] Astellas, AST ANN TOPL RES PHA
  • [6] Duration of Menopausal Vasomotor Symptoms Over the Menopause Transition
    Avis, Nancy E.
    Crawford, Sybil L.
    Greendale, Gail
    Bromberger, Joyce T.
    Everson-Rose, Susan A.
    Gold, Ellen B.
    Hess, Rachel
    Joffe, Hadine
    Kravitz, Howard M.
    Tepper, Ping G.
    Thurston, Rebecca C.
    [J]. JAMA INTERNAL MEDICINE, 2015, 175 (04) : 531 - 539
  • [7] Randomized placebo- and active-controlled study of desvenlafaxine for menopausal vasomotor symptoms
    Bouchard, P.
    Panay, N.
    de Villiers, T. J.
    Vincendon, P.
    Bao, W.
    Cheng, R. J.
    Constantine, G.
    [J]. CLIMACTERIC, 2012, 15 (01) : 12 - 20
  • [8] Caan B, 2015, MENOPAUSE, V22, P607, DOI [10.1097/GME.0000000000000364, 10.1097/gme.0000000000000364]
  • [9] Cano A, 2022, INT MENOPAUSE SOC 18
  • [10] TX-001HR is associated with a clinically meaningful effect on severity of moderate to severe vasomotor symptoms in the REPLENISH trial
    Constantine, Ginger D.
    Simon, James A.
    Kaunitz, Andrew M.
    Pickar, James H.
    Revicki, Dennis A.
    Graham, Shelli
    Bernick, Brian
    Mirkin, Sebastian
    [J]. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2020, 27 (11): : 1236 - 1241
12345